{
    "Clinical Trial ID": "NCT01106040",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Intent-To-Treat",
        "  Participants received a single dose of 50 \u03bcg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  The patient has provided written informed consent with HIPAA authorization.",
        "  The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.",
        "  The patient is at least 18 years of age at the time of consent.",
        "  The patient has an ECOG performance status of Grade 0 - 2 (see Appendix A).",
        "  The patient has a clinical negative node status at the time of study entry (i.e. T0-4, N0, M0, see Appendix D and E).",
        "  If of childbearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.",
        "  Melanoma Patients",
        "  The patient has a diagnosis of primary melanoma. Breast Cancer Patients",
        "  The patient has a diagnosis of primary breast cancer.",
        "  Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.",
        "Exclusion Criteria:",
        "  The patient is pregnant or lactating.",
        "  The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0, see Appendix D and E).",
        "  The patient has a known hypersensitivity to Lymphazurin.",
        "  The patient has participated in another investigational drug study within 30 days of scheduled surgery.",
        "  Melanoma Patients",
        "  The patient has a tumor with a Breslow depth less than 0.75mm.",
        "  Patient has had preoperative chemotherapy, immunotherapy, or radiation therapy.",
        "  Patient has been diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin.",
        "  Patient has undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma.",
        "  Patient has undergone a wide excision for their primary melanoma (>1 cm in dimension) or complex reconstruction (rotation, free flap, or skin graft of any type).",
        "  Breast Cancer Patients",
        "  The patient has bilateral primary breast cancers or multiple tumors within their breast.",
        "  Patient has had prior surgical procedures such as breast implants, reduction mammoplasty, or axillary surgery.",
        "  Patient is scheduled for bilateral mastectomy unless for cosmetic reasons and the contraindicated breast will not undergo lymph node mapping.",
        "  Patient has had preoperative radiation therapy to the affected breast or axilla."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Concordance of Blue Dye and Lymphoseek",
        "  The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.",
        "  Time frame: Surgery after injections of Lymphoseek and blue dye",
        "Results 1: ",
        "  Arm/Group Title: Intent-To-Treat",
        "  Arm/Group Description: Participants received a single dose of 50 \u03bcg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.",
        "  Overall Number of Participants Analyzed: 133",
        "  Overall Number of Units Analyzed",
        "  Type of Units Analyzed: Lymph Nodes  Measure Type: NumberNumber (95% Confidence Interval)Unit of Measure: Proportion of Lymph Nodes: 1.0000        (0.9840 to 1.0000)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 8/153 (5.23%)",
        "  Bradycardia  [1]1/153 (0.65%)",
        "  Tachycardia  [1]1/153 (0.65%)",
        "  Cellulitis  [1]2/153 (1.31%)",
        "  Herpes Zoster Ophthalmic  [1]1/153 (0.65%)",
        "  Seroma  [1]1/153 (0.65%)",
        "  Syncope  [1]1/153 (0.65%)",
        "  Asthma  [1]1/153 (0.65%)"
    ]
}